repeated relapses. The standard management for patients who have asymptomatic follicular lymphoma is to “watch and wait.” In the pre-rituximab era, multiple randomized phase III trials compared immediate treatment with chemotherapy and observation for
Search Results
Optimization of Postremission Therapy in Follicular Lymphoma: Efficacy of Rituximab Maintenance
Rupali Roy and Leo I. Gordon
Multiple Myeloma: Advances Reported in 2013 Are Useful in the Clinic
Kenneth Anderson
the results are very impressive, indeed,” Dr. Anderson noted. “This is exciting because it is an all-oral regimen without much neuropathy.” Relapsed/Refractory Disease “We have very exciting initial therapy, we have consolidation treatments
Novel Therapies Potentially Available for Pediatric B-Cell Non-Hodgkin Lymphoma
Paul D. Harker-Murray, Lauren Pommert, and Matthew J. Barth
neutropenia, and infections, compared with other pediatric B-NHL chemotherapy backbones, 17 , 23 and has been adopted as the standard therapy for this group of patients. Relapsed B-NHL Relapsed pediatric B-NHL has a very poor prognosis with survival rates
Chronic Lymphocytic Leukemia: Individualizing Treatment Approach
Andrew D. Zelenetz
“Chronic lymphocytic leukemia [CLL] is a continuum of disease. Although a number of patients will never be treated for their disease (indolent CLL; “early” asymptomatic), most patients will move on to active CLL (“later” symptomatic) or relapsed
Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Patrick Brown, Hiroto Inaba, Colleen Annesley, Jill Beck, Susan Colace, Mari Dallas, Kenneth DeSantes, Kara Kelly, Carrie Kitko, Norman Lacayo, Nicole Larrier, Luke Maese, Kris Mahadeo, Ronica Nanda, Valentina Nardi, Vilmarie Rodriguez, Jenna Rossoff, Laura Schuettpelz, Lewis Silverman, Jessica Sun, Weili Sun, David Teachey, Victor Wong, Gregory Yanik, Alyse Johnson-Chilla, and Ndiya Ogba
management of ALL. This portion of the NCCN Guidelines discusses recommendations for the diagnosis and workup of pediatric ALL and focuses on frontline and relapsed/refractory (R/R) management strategies for B-ALL, T-ALL, and infants with ALL. For the
Acute Lymphoblastic Leukemia, Version 2.2015
Joseph C. Alvarnas, Patrick A. Brown, Patricia Aoun, Karen Kuhn Ballen, Stefan K. Barta, Uma Borate, Michael W. Boyer, Patrick W. Burke, Ryan Cassaday, Januario E. Castro, Peter F. Coccia, Steven E. Coutre, Lloyd E. Damon, Daniel J. DeAngelo, Dan Douer, Olga Frankfurt, John P. Greer, Robert A. Johnson, Hagop M. Kantarjian, Rebecca B. Klisovic, Gary Kupfer, Mark Litzow, Arthur Liu, Arati V. Rao, Bijal Shah, Geoffrey L. Uy, Eunice S. Wang, Andrew D. Zelenetz, Kristina Gregory, and Courtney Smith
, the treatment of relapsed/refractory ALL, and the role of minimal residual disease (MRD) evaluation. Please refer to NCCN.org for the complete guidelines. ALL is a heterogeneous hematologic disease characterized by the proliferation of immature
NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017
Patrick A. Brown, Bijal Shah, Amir Fathi, Matthew Wieduwilt, Anjali Advani, Patricia Aoun, Stefan K. Barta, Michael W. Boyer, Teresa Bryan, Patrick W. Burke, Ryan Cassaday, Peter F. Coccia, Steven E. Coutre, Lloyd E. Damon, Daniel J. DeAngelo, Olga Frankfurt, John P. Greer, Hagop M. Kantarjian, Rebecca B. Klisovic, Gary Kupfer, Mark Litzow, Arthur Liu, Ryan Mattison, Jae Park, Jeffrey Rubnitz, Ayman Saad, Geoffrey L. Uy, Eunice S. Wang, Kristina M. Gregory, and Ndiya Ogba
pathogenesis of ALL, the incorporation of risk-adapted therapy, the advent of new targeted agents, and the use of allogeneic hematopoietic cell transplantation (HCT). However, the treatment of patients who experience relapse after initial therapy remains a
Chronic Lymphocytic Leukemia: State of the Art and Beyond
John C. Byrd
Agents for Relapsed Disease Similarly, with relapsed disease, treatment is started based on symptoms. The NCCN Guidelines list many options; however, with the approval of ibrutinib, the traditional second-line therapies have largely become irrelevant
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017
William G. Wierda, Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Paolo Caimi, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Richard T. Hoppe, Steven M. Horwitz, Mark S. Kaminski, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Michael G. Martin, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth Roberts, Ayman A. Saad, Erin D. Snyder, Lubomir Sokol, Lode J. Swinnen, Julie M. Vose, Joachim Yahalom, Mary A. Dwyer, and Hema Sundar
Oncology (NCCN Guidelines) for CLL/SLL for the treatment of patients with newly diagnosed or relapsed or refractory CLL/SLL. First-Line Therapy First-line therapy with fludarabine/cyclophosphamide/rituximab (FCR) results in high response rates and
An Update on the Role of Interim Restaging FDG-PET in Patients With Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
Craig H. Moskowitz, Andrew Zelenetz, and Heiko Schoder
unless disease progression was seen at this time point. At a median follow-up of 3 years, 43 patients experienced progression during therapy and 12 experienced relapse. After 2 cycles of treatment, 52 patients had positive FDG-PET results and 208 had
